Medpace
MEDP
$393.42
-22.63%
Medpace Holdings, Inc. is a late-stage contract research organization (CRO) that provides full-service drug-development and clinical trial services primarily to small and midsize biotechnology, pharmaceutical, and medical device firms, operating within the healthcare industry's medical diagnostics and research sector. The company has established itself as a key player in the CRO space by focusing on a full-service model for smaller biopharma clients, which often lack extensive in-house development capabilities. The current investor narrative is heavily influenced by the stock's extreme volatility, as evidenced by a dramatic price collapse and partial recovery in early 2026, which has sparked debate over whether this represents a market overreaction or a fundamental reassessment of its growth trajectory amidst a broader sector selloff.…
MEDP
Medpace
$393.42
Related headlines
Investment Opinion: Should I buy MEDP Today?
Rating & Thesis: Hold. Medpace is a high-quality company with exceptional growth and profitability, but its extreme valuation premium and demonstrated volatility create an unfavorable risk/reward profile at the current price, warranting a neutral stance pending a better entry point or evidence of sustained execution.
Supporting Evidence: The stock trades at a 35.91x trailing PE, a 25% premium to its own forward PE of 27.06x, implying high growth expectations. While revenue growth is accelerating (32% YoY) and net margins are expanding (up over 400 bps sequentially to 19.07%), these positives appear priced in. The valuation premium is stark when considering the sector average PE is in the low-to-mid 20s. Strong free cash flow generation ($708.7M TTM) and a solid balance sheet (D/E 0.55) are supportive but not sufficient to justify the current multiple alone.
Risks & Conditions: The two biggest risks are valuation multiple contraction and a growth slowdown triggering the high volatility inherent in its 1.39 beta. This Hold rating would upgrade to a Buy if the forward PE compresses toward 22x (closer to sector average) or if revenue growth accelerates further above 35% for multiple quarters, confirming its premium is deserved. It would downgrade to a Sell if revenue growth decelerates below 20% or net margins contract sequentially. Based on the data, the stock is overvalued relative to its industry peers, though fairly valued relative to its own elevated historical range if hyper-growth persists.
Sign up to view all
MEDP 12-Month Price Forecast
Medpace is a fundamental powerhouse trapped in a volatile, expensive stock. The 12-month outlook is a tug-of-war between its operational excellence and its demanding valuation. The base case (55% probability) of choppy, range-bound trading is most likely, as the market requires proof that the current hyper-growth is sustainable before rewarding the stock further. The stance is neutral due to the balanced risk/reward; the upside to the bull case (~20%) is roughly matched by the downside to the bear case (~25-50%). We would upgrade to bullish on a pullback to a forward PE near 22x or evidence of another quarter of accelerating growth. A downgrade to bearish would follow a confirmed breakdown below $450 with deteriorating fundamentals.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Medpace's 12-month outlook, with a consensus price target around $511.45 and implied upside of +30.0% versus the current price.
Average Target
$511.45
4 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
4
covering this stock
Price Range
$315 - $511
Analyst target range
Analyst coverage for MEDP is limited, with only 4 analysts providing estimates, indicating this is a mid-cap stock with selective institutional following. The consensus sentiment, inferred from recent rating actions, appears mixed but leaning towards neutral or cautious, with several firms maintaining Hold or Market Perform ratings. The average estimated EPS for the forward period is $25.05, with a range from $23.46 to $26.24. The target price range and implied upside cannot be calculated from the provided data as specific price targets are not given. The range of analyst actions signals moderate uncertainty. Recent institutional ratings show a pattern of stabilization following the volatile price drop, with Barclays maintaining Underweight, TD Cowen upgrading from Sell to Hold, and Jefferies upgrading from Hold to Buy in February 2026. This mix of upgrades and maintained cautious stances reflects the ongoing debate about the stock's valuation and growth sustainability post-selloff. The limited number of covering analysts can lead to higher volatility and less efficient price discovery compared to more widely followed names.
Bulls vs Bears: MEDP Investment Factors
The evidence presents a tense battle between Medpace's stellar fundamental performance and its precarious, premium valuation in a volatile market. The bull case is powerfully supported by accelerating 32% revenue growth, expanding margins to 19% net income, and robust cash generation. However, the bear case is equally compelling, anchored by an extreme valuation premium (35.9x trailing PE) that leaves no margin for error, coupled with demonstrated stock price volatility (beta 1.39, -33% drawdown). Currently, the bearish arguments on valuation and volatility hold stronger evidence, as the stock's price action shows it remains well below its highs despite strong fundamentals, indicating the market is prioritizing risk and multiple compression. The single most important tension is whether the company's exceptional growth and margin profile can persist long enough to justify and grow into its lofty valuation, or if a slowdown in biotech funding or operational misstep will trigger a severe derating.
Bullish
- Accelerating Revenue Growth: Q4 2025 revenue grew 32.03% YoY to $708.45 million, with sequential acceleration from $603.31M in Q2 to $659.90M in Q3. This demonstrates sustained, robust demand for Medpace's CRO services, particularly in high-growth therapeutic areas like Metabolic and Oncology.
- Expanding Profitability Margins: Net margin expanded sequentially from 14.96% in Q2 to 19.07% in Q4 2025, showcasing strong operating leverage. The company's Q4 operating margin of 21.63% and ROE of 98.27% (amplified by buybacks) indicate highly efficient capital deployment and cost management.
- Strong Cash Generation & Balance Sheet: Generated $708.69M in TTM free cash flow with a conservative debt-to-equity ratio of 0.55. This provides ample internal funding for growth and strategic initiatives without financial strain, a key advantage in a capital-intensive industry.
- Recovery from Oversold Levels: The stock is up 14.47% over the past month and trades at 82.8% of its 52-week range, recovering from a low of $250.05. This technical rebound, coupled with a +7.11% 1-month relative strength vs. SPY, suggests the severe February sell-off may have been an overreaction.
Bearish
- Extreme Valuation Premium: Trading at a trailing PE of 35.91x and forward PE of 27.06x, Medpace commands a significant premium to typical CRO sector averages (low-to-mid 20s). This leaves minimal room for error and makes the stock vulnerable to multiple compression if growth decelerates.
- High Volatility & Recent Drawdown: The stock has a beta of 1.39 and experienced a -32.96% maximum drawdown, culminating in a 52-week low of $250.05 in February 2026. This extreme volatility, driven by market structure and liquidity, poses a significant risk for investors with low risk tolerance.
- Limited Analyst Coverage & Uncertainty: Only 4 analysts cover the stock, leading to less efficient price discovery and higher volatility. The mixed analyst sentiment (Barclays maintains Underweight) reflects ongoing uncertainty about the sustainability of its premium valuation post-selloff.
- Weak Current Ratio: A current ratio of 0.74 is low, indicating potential short-term liquidity constraints relative to liabilities. While typical for service firms with minimal inventory, it requires careful management of working capital.
MEDP Technical Analysis
The prevailing price trend for MEDP is a volatile downtrend from its highs, characterized by a sharp collapse and a subsequent partial recovery. Despite a strong 1-year price change of +75.71%, the stock is currently trading at approximately 82.8% of its 52-week range, calculated from a low of $250.05 to a high of $628.916, suggesting it is recovering from a significant drawdown but remains well off its peak. This positioning indicates the stock is in a recovery phase from oversold levels, but the path from the February lows has been choppy, reflecting high uncertainty. Recent short-term momentum shows a stark divergence from the longer-term trend, with a strong 1-month gain of +14.47% contrasting with a 3-month loss of -14.78%. This suggests the stock is attempting a rebound from deeply oversold conditions, with the positive 1-month relative strength of +7.11% against the SPY indicating it is outperforming the market in the very near term, potentially signaling a mean reversion or short-covering rally. Key technical levels are clearly defined by the 52-week high of $628.916 as major resistance and the 52-week low of $250.05 as critical support. A breakout above resistance would signal a full recovery of the February sell-off, while a breakdown below support would indicate a new downtrend phase. The stock's beta of 1.391 confirms it is approximately 39% more volatile than the broader market, which is critical for risk management given its demonstrated propensity for large swings, such as the -32.96% maximum drawdown.
Beta
1.39
1.39x market volatility
Max Drawdown
-36.6%
Largest decline past year
52-Week Range
$284-$629
Price range past year
Annual Return
+35.4%
Cumulative gain past year
| Period | MEDP Return | S&P 500 |
|---|---|---|
| 1m | -14.6% | +8.5% |
| 3m | -33.1% | +2.8% |
| 6m | -35.0% | +4.6% |
| 1y | +35.4% | +32.3% |
| ytd | -31.1% | +3.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MEDP Fundamental Analysis
Medpace's revenue trajectory remains robustly positive, with Q4 2025 revenue of $708.45 million representing a significant 32.03% year-over-year growth. This acceleration is evident when comparing sequential quarters; revenue grew from $603.31 million in Q2 to $659.90 million in Q3, and then to $708.45 million in Q4, indicating sustained demand for its CRO services. Segment data shows Metabolic ($249.81 million) and Oncology ($195.92 million) as the largest revenue contributors, driving the overall growth. The company is highly profitable with expanding margins. Q4 2025 net income was $135.13 million, yielding a net margin of 19.07%. Gross margin for the quarter was 28.98%, and the operating margin was 21.63%. Profitability has improved sequentially, as the net margin expanded from 14.96% in Q2 to 16.84% in Q3 and to 19.07% in Q4, demonstrating effective cost management and operating leverage. The balance sheet and cash flow position is strong, characterized by high profitability and solid cash generation. The debt-to-equity ratio is a manageable 0.55, indicating a conservative capital structure. The company generated substantial free cash flow of $708.69 million on a trailing twelve-month basis, providing ample internal funding for growth. The return on equity is exceptionally high at 98.27%, though this is amplified by share buybacks reducing equity, and the current ratio is 0.74, which is low but typical for a services business with minimal inventory.
Quarterly Revenue
$708450000.0B
2025-12
Revenue YoY Growth
+0.32%
YoY Comparison
Gross Margin
+0.28%
Latest Quarter
Free Cash Flow
$708687000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MEDP Overvalued?
Given a positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE is 35.91x, while the forward PE is 27.06x, based on estimated EPS. The gap between trailing and forward multiples implies the market expects earnings growth to continue, as the forward multiple represents a 25% discount, pricing in future profit expansion. Compared to sector averages, Medpace trades at a significant premium. Its trailing PE of 35.91x and forward PE of 27.06x are well above typical CRO/industry averages, which often range in the low-to-mid 20s. This premium is likely justified by the company's superior growth profile, with 32% YoY revenue growth and expanding margins, and its focused service model for the high-growth biotech segment. Historically, the stock's current trailing PE of 35.91x sits above its own historical range observed in recent quarters, where it has fluctuated between approximately 20x and 36x. Trading near the top of its historical band suggests the market is pricing in optimistic expectations for sustained high growth and margin performance, leaving little room for operational missteps.
PE
35.9x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 18x~40x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
28.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Medpace's primary financial risk is its valuation dependency on continued hyper-growth. With a trailing PE of 35.9x, any deceleration from the current 32% revenue growth rate could trigger significant multiple compression. The low current ratio of 0.74, while industry-typical, indicates reliance on consistent cash conversion from operations to meet short-term obligations. Furthermore, the exceptionally high ROE of 98.27% is partly a function of aggressive share buybacks reducing equity, a strategy that may not be sustainable indefinitely and amplifies earnings per share volatility.
Market & Competitive Risks: The stock faces acute valuation compression risk, trading at a ~35-40% premium to typical CRO sector PE multiples. Its high beta of 1.39 makes it disproportionately sensitive to broader market selloffs and sector rotations out of growth stocks, as evidenced by its -17.45% 3-month relative underperformance versus the SPY. Competitive risks include potential pricing pressure from larger CROs and dependence on the funding health of its small/mid-size biopharma client base, which is more vulnerable to economic downturns than large pharmaceutical companies.
Worst-Case Scenario: The worst-case scenario involves a simultaneous slowdown in biotech client spending and a broader market downturn compressing growth stock multiples. This could trigger a cascade of analyst downgrades, leading the stock to re-test its 52-week low of $250.05. From the current price of $520.60, this represents a catastrophic loss of approximately -52%. A more realistic, yet severe, bear case would see the stock fall to the lower end of its historical PE range (~20x), applied to a lowered earnings estimate, implying a downside risk of -30% to -40%.
FAQ
The key risks are: 1) Valuation Compression: The primary risk is its high PE multiple (35.9x) contracting if growth slows, which could cause significant price decline regardless of business health. 2) Extreme Volatility: With a beta of 1.39 and a recent -32.96% maximum drawdown, the stock is prone to wild swings, as seen in February 2026. 3) Client Concentration Risk: Its focus on small/mid-size biotech firms makes it sensitive to sector funding cycles. 4) Limited Coverage: Only 4 analysts follow the stock, which can lead to exaggerated price moves on news and less efficient price discovery.
The 12-month forecast presents three scenarios. The Base Case (55% probability) sees the stock trading between $480 and $550, as strong fundamentals are offset by a rich valuation, leading to choppy performance. The Bull Case (25% probability) targets $600 to $629, requiring sustained >30% growth and a market rally. The Bear Case (20% probability) warns of a drop to $250-$400 if growth falters, triggering a derating. The Base Case is most likely, centered on the stock's current trading range, with the key assumption being that revenue growth moderates but remains robust in the mid-to-high 20% range.
MEDP is overvalued relative to the broader CRO sector but may be fairly valued relative to its own growth profile if execution remains flawless. Its trailing PE of 35.91x and forward PE of 27.06x are significantly above typical industry averages in the low-to-mid 20s. The market is paying a premium for its accelerating revenue growth (32% YoY) and expanding profitability. This valuation implies the market expects this hyper-growth to persist. If growth decelerates, the stock is vulnerable to a sharp derating.
MEDP is a good buy only for aggressive, risk-tolerant investors who believe its exceptional growth can continue. The stock offers exposure to a high-quality CRO with 32% revenue growth and 19% net margins. However, with a trailing PE of 35.9x (a premium to peers) and a history of severe volatility (beta 1.39, -33% drawdown), the risk/reward is balanced at the current price. It is not a good buy for conservative investors or those seeking stable returns. A better entry point would be on a pullback that reduces the valuation premium.
MEDP is more suitable for a long-term (3+ year) investment horizon for investors who can withstand severe interim volatility. Its high beta of 1.39 and lack of dividend make it a poor choice for short-term trading or income. A long-term horizon allows time for the company's fundamental growth to potentially justify its valuation and for investors to ride out the inevitable sharp drawdowns. However, given the valuation risks, even long-term investors should consider dollar-cost averaging rather than making a large lump-sum purchase at current levels.